Safety and Efficacy of Medications COVID-19

• Status: Completed
• Trial end date: 2022-03-31
• Target enrollment: 0
• Participant gender: All

Summary

We performed a quasi-experimental open-label pragmatic study alternating standard of care (SOC) and oral bedtime melatonin (OBM) at different high doses over 4 consecutive time periods enrolling all consecutive RT-PCR SARS-CoV-2 severe Covid-19 admissions.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital San Carlos, Madrid
• Treatments: Melatonin

Criteria

Inclusion Criteria:

• Positive RT-PCR for SARS-CoV-2

Exclusion Criteria:

• Anticipated death within 48 hours or paliative care